Iqgen-X Pharma Private Limited, a active private limited company, was established on 13 October 2016 in Navi Mumbai, Maharashtra, India. Engaging in drug formulation & development within the professional, scientific and technical sector, it holds CIN: U74999MH2016PTC286716. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹2.00 Cr and a paid-up capital of ₹1.13 Cr.
It upholds a compliant status. Employing 34 professional, Its leadership includes Yatendra Kumar (Director), Karan Jasjit Singh (Additional Director), Yogita Mandar Kodgule (Director). Past directors included Prabhakaran Balakrishnan Nair, Mousumi Satyanarayana Vemula, Urmila Devi Vemula. It holds ₹2.28 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2023, with the balance sheet filed on 31 March 2023. It is based at A-165, Ttc Industrial Area, Khairane., Navi Mumbai, Maharashtra, 400705.
U74999MH2016PTC286716
286716
13 October 2016
₹2.00 Cr
₹1.13 Cr
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Iqgen-X Pharma Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Yatendra Kumar | Director | 01 Apr 2017 | Current |
| Karan Jasjit Singh | Additional Director | 16 Oct 2020 | Current |
| Yogita Mandar Kodgule | Director | 01 Apr 2017 | Current |
| Mandar Madhukar Kodgule | Director | 01 Apr 2017 | Current |
| Madhu Hariharan | Director | 01 Apr 2017 | Current |
| Parizad Adil Elchidana | Additional Director | 30 Sep 2021 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Sep 2021 | Past |
| Pramod Abcsdd | Director | 16 Jul 2020 | Past |
| Pramod Abcsdd | Director | 01 Apr 2017 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Iqgen-X Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 13.64% decrease. The company also saw a substantial improvement in profitability, with a 86.35% increase in profit. The company's net worth moved up by a moderate rise of 5.17%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Iqgen-X Pharma had a promoter holding of 40.80% and a public holding of 59.20%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹22,800,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Jul 2020 | Canara Bank | ₹2.80 M | Open |
| 25 Sep 2017 | Canara Bank | ₹2.00 Cr | Open |
Explore comprehensive loan charge details -
Iqgen-X Pharma has a workforce of 34 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Iqgen-X Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Iqgen-X Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Iqgen-X Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records. was completed.
Progress on Iqgen-X Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Mumbai. was documented.
Parizad Adil Elchidana was appointed as a Additional Director was appointed as a Additional Director on 30 Sep 2021 & has been associated with this company since 4 years 2 months . was recorded as a recent event.
Progress on Karan Jasjit Singh was appointed as a Additional Director was appointed as a Additional Director on 16 Oct 2020 & has been associated with this company since 5 years 2 months . was documented.
The activity A charge with Canara Bank of Rs. 2.00 Cr registered on 25 Sep 2017 with Charge ID 100135679 was modified on 29 Aug 2020. was completed.
A charge with Canara Bank amounted to Rs. 0.28 Cr with Charge ID 100355277 was registered on 28 Jul 2020. was recorded as a recent event.
The CIN of Iqgen-X Pharma Private Limited is U74999MH2016PTC286716.
Iqgen-X Pharma Private Limited is headquartered at A-165, Ttc Industrial Area, Khairane., Navi Mumbai, Maharashtra, 400705.
Iqgen-X Pharma Private Limited was incorporated on 13 October 2016.
The current directors of Iqgen-X Pharma Private Limited are
The primary industry of Iqgen-X Pharma Private Limited is Professional, Scientific And Technical.
Iqgen-X Pharma Private Limited is unlisted.
The authorized capital of Iqgen-X Pharma Private Limited is ₹2.00 Cr, and the paid-up capital is ₹1.13 Cr.
The compliance status of Iqgen-X Pharma Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX